Introduction

Dapsone induced hypersensitivity syndrome also referred to as ‘sulfone syndrome’ is increasingly being recognized in clinical practice these days. It can present with varied local and systemic manifestations involving organ dysfunction.  We hereby are presenting a case of hypersensitivity of this drug which presented in a similar fashion as that of sepsis.

1. Lowe J, Smith M. The chemotherapy of leprosy in Nigeria. Int J Lepr, 1949; 17: 181–195
2. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. Kosseifi SG, Guha B, Nassour DN, Chi DS, Krishnaswamy GJ Occup Med Toxicol. 2006 Jun 6; 1():9.
3. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal. Pandey B, Shrestha K, Lewis J, Hawksworth RA, Walker SL Trop Doct. 2007 Jul; 37(3):162-3.
4. Dapsone and sulfones in dermatology: overview and update. Zhu YI, Stiller MJ ; J Am Acad Dermatol. 2001 Sep; 45(3):420-34.
5. Janier M, Guillevin L, Badillet G. Pulmonary eosinophilia associated with dapsone. 1994;343:860–861. doi: 10.1016/S0140-6736(94)92066-4.
6. Dapsone induced cholangitis as a part of dapsone syndrome: a case report.Itha S, Kumar A, Dhingra S, Choudhuri GBMC Gastroenterol. 2003 Aug 11; 3():21.
7. Reactive metabolites and adverse drug reactions: clinical considerations. Knowles SR, Shapiro LE, Shear NH; Clin Rev Allergy Immunol. 2003 Jun; 24(3):229-38.

Rohit Vashisht

Dept. of Infectious Diseases, Apollo Hospital, Chennai